Viscosupplementation in Patients With Hemophilic Arthropathy

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01748201
Collaborator
(none)
13
1
1
3.9
3.3

Study Details

Study Description

Brief Summary

Hemophilia is a recessive X chromosome linked genetic disorder of blood coagulation that affects about one in every ten thousand people. Hemarthrosis, which you can begin in childhood, promptly leads to degenerative changes of the articular cartilage which culminate in deformity and degenerative changes early, known as hemophilic arthropathy, which is the most common complication of hemophilia. Aside administration of clotting factor, treatment should address the degenerative changes already present in patients joints. Our objective is to evaluate the effectiveness of articular washing followed by infiltration with corticosteroids and hylan G-F 20, followed by a program of home exercises and/or academy as the previous level of hemophilia patients, in relation to pain relief, and improved function and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Joint lavage and viscosupplementation
Phase 4

Detailed Description

Hemophilia is a recessive X chromosome linked genetic disorder of blood coagulation that affects about one in every ten thousand people. There are two main types of hemophilia. Hemophilia A or classical hemophilia corresponds to 80% of the cases, and is caused by a deficiency or change of factor VIII. Hemophilia B is caused by deficiency or amendment of factor IX, and represents about 20%. Patients with hemophilia type A or B have the same clinical presentation. Cases with moderate or severe hemophilia exhibit a tendency to spontaneous bleeding or after minimal trauma, being the joints the most frequent sites of hemorrhage. The joints most commonly affected are the knees, followed by the elbows, ankles, shoulders and hips. Hemarthrosis, which you can begin in childhood, promptly leads to degenerative changes of the articular cartilage which culminate in deformity and degenerative changes early, known as hemophilic arthropathy, which is the most common complication of hemophilia. The hemophilic arthropathy is highly debilitating and consumes a large amount of resources for the treatment of hemophilic patients. Currently, by the adequate administration of the clotting factor, the hemophilic patient has a life expectancy of next to normal. Therefore other forms of treatment must be researched; they can be palliative or modifiers of the natural history of disease, to try to postpone the need for arthroplasty . Our objective is to evaluate the effectiveness of treatment, consisting of articular washing followed by infiltration with corticosteroids and hylan G-F 20, followed by a program of home exercises and/or academy as the previous level of hemophilia patients, in relation to pain relief, and improved function and quality of life.

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Viscosupplementation in Patients With Hemophilic Arthropathy
Study Start Date :
Nov 1, 2012
Actual Primary Completion Date :
Mar 1, 2013
Actual Study Completion Date :
Mar 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: Joint lavage and viscosupplementation

The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.

Procedure: Joint lavage and viscosupplementation
The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
Other Names:
  • intra-articular injection
  • Outcome Measures

    Primary Outcome Measures

    1. WOMAC [12 months]

      Evaluation of patient's symptoms using Western Ontario and McMaster Universities osteoarthritis index (WOMAC

    2. VAS [12 months]

      Visual analogic scale for pain assessment

    3. Lequesne [12 months]

      Evaluation of patient's symptoms using Lequesne questionaire

    Secondary Outcome Measures

    1. SF-36 [12 months]

      Evaluation of patient's quality of life using the quality of life's questionaire (SF-36)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients with hemophilia A or B;

    • symptomatic arthropathy;

    Exclusion Criteria:
    • inadequate follow-up;

    • Bleeding elsewhere as to not allow for functional evaluation;

    • complications of Arthrocentesis (infection).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Instituto de Ortopedia e Traumatologia HC-FMUSP São Paulo SP Brazil 05410-000

    Sponsors and Collaborators

    • University of Sao Paulo General Hospital

    Investigators

    • Principal Investigator: Marcia U Rezende, Phd, FMUSP

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    University of Sao Paulo General Hospital
    ClinicalTrials.gov Identifier:
    NCT01748201
    Other Study ID Numbers:
    • 0199/11
    First Posted:
    Dec 12, 2012
    Last Update Posted:
    Sep 10, 2013
    Last Verified:
    Sep 1, 2013
    Keywords provided by University of Sao Paulo General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 10, 2013